The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…If power was above the threshold (<i>z</i> > 1.96) for a minimum of 10% of the time window (500 ms) after the cue, the channel was considered hemifield-selective. …”

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

Wnt signaling decreases the recruitment of RAB8a to basal bodies. by Cheng Yuan (160315)

Knockdown of ATP2C1 results in a minor decrease of [Ca²⁺] in WPB. by Julian Terglane (12975565)

Subjects:

FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease. by Joshua Looker (21390948)

“…<p>Effective contact rate over time for the different modelling scenarios considered: fixed, continuously increasing, continuously decreasing and with a step-decrease.</p>…”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation. by Sarah E. Copeland (13951506)

“…Large circles show mean of cells from 5 fields of view from a single animal. …”

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

LBM-based approach using synchronous transformation with a time step of 0.43s, PNGM-based method using asynchronous transformation with a 5s time step, VGA using explicit scheme wi... by Mouad Klai (20818364)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects: